Dr. Libby is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
P.O. Box 99803
CE3-300
Seattle, WA 98139Phone+1 505-259-7714Fax+1 206-606-1190- Is this information wrong?
Summary
- Dr. Libby received his B.S. from the University of Texas at El Paso and his M.D. from the University of Texas Health Science Center at Houston. He completed his Internal Medicine residency and chief residency at the University of New Mexico(UNM) in Albuquerque. He was a Fellow in Hematology at UNM and at UNC Chapel Hill.
Specialty & Clinical Expertise
Multiple myeloma, Plasma cell leukemia, Amyloidosis (all types), Waldenstrom’s macroglobulinemia, Plasmacytomas, POEMS Syndrome, smoldering multiple myeloma, MGUS.
Research Interests
Dr. Libby is the primary investigator for numerous Phase I,II and III clinical trials in multiple myeloma, amyloidosis and Waldenstrom's macroglobulinemia.
Education & Training
- University of New Mexico School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2005
- University of New Mexico School of MedicineResidency, Internal Medicine, 1984 - 1987
- McGovern Medical School at UTHealthClass of 1984
Certifications & Licensure
- CA State Medical License 2024 - 2026
- WA State Medical License 2011 - 2026
- OR State Medical License 2023 - 2025
- DC State Medical License 2022 - 2024
- NM State Medical License 1985 - 2013
- American Board of Internal Medicine Hematology
Clinical Trials
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 7 citationsSix-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymph...Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N Lib...> ;Journal of Clinical Oncology. 2022 Oct 1
- 2 citationsHealth-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the AN...Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, Arnaud Jaccard, Hans C Lee, Simon Gibbs, Peter Mollee, Christopher Venner, Jin Lu, Stefan Schönland, Mosh...> ;American Journal of Hematology. 2022 Jun 1
- 262 citationsDiagnosis and Management of Multiple Myeloma: A Review.Andrew J Cowan, Damian J Green, Mary Kwok, Sarah Lee, David G Coffey, Leona A Holmberg, Sherilyn Tuazon, Ajay K Gopal, Edward N Libby> ;JAMA. 2022 Feb 1
- Join now to see all
Abstracts/Posters
- Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Treating Cancer Differently in Older PatientsSeptember 10th, 2015
Professional Memberships
- Member
Hospital Affiliations
- UW Medicine/University of Washington Medical CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: